Publications by authors named "Matthias Ludwig"

Claim this Profile
P
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Timothy A Yap, David S P Tan, Anastasios Stathis, Geoffrey I Shapiro, Satoru Iwasa, Matthias Ludwig

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Timothy A Yap, David S P Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Matthias Ludwig

Cancer Discov· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.
Julia Winkler, Mark Goldammer, Matthias Ludwig, Beate Rohde, Christian Zurth

Eur J Drug Metab Pharmacokinet· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
Christian Zurth, Barbara Schuett, Manuela Casjens, Matthias Ludwig, Katrin Waellnitz

Clin Pharmacol Drug Dev· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
Joachim Höchel, Barbara Schuett, Matthias Ludwig, Christian Zurth

Int J Clin Pharmacol Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.
Michael-Friedrich Boettcher, Roland Heinig, Carsten Schmeck, Christian Kohlsdorfer, Matthias Ludwig

Br J Clin Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Erich Brendel, Matthias Ludwig, Chetan Lathia, Caroline Robert, Stanislas Ropert

Cancer Chemother Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Affinity of 1-aryl-1,2,3,4-tetrahydroisoquinoline derivatives to the ion channel binding site of the NMDA receptor complex.
Matthias Ludwig, Cornelia E Hoesl, Georg Höfner, Klaus T Wanner

Eur J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis